Antiangiogenic Drugs in the Treatment of Endometriosis

Matteo Morotti, Simone Ferrero
Reproductive sciences (Thousand Oaks, Calif.) · 2012 · vol. 20(3) , pp. NP1–NP2 · doi:10.1177/1933719112468955 · PMID:23275467 · W2017055067
letter OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-13 ⓘ

This review discusses the efficacy of antiangiogenic drugs, such as bevacizumab and sorafenib, for treating endometriosis, citing animal models and exploring their mechanisms and potential toxicities.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This short piece discusses the rationale for antiangiogenic drugs as a therapeutic approach in endometriosis, focusing on how inhibiting angiogenesis could affect endometriotic lesion establishment and progression. Drawing on prior preclinical and review evidence, it highlights agents such as bevacizumab and sorafenib and considers related pharmacologic considerations. Because the text is essentially a commentary/editorial overview rather than a new experimental study with its own study population, it provides limited direct clinical efficacy data. This paper is centrally about endometriosis — it focuses on antiangiogenic drug strategies for endometriosis treatment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,061 characters · extracted from oa-doi-fallback · click to expand
References Ozer H, Boztosun A, Açmaz G, et al. The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model [published online August 15, 2012]. Reprod Sci. 2012. Ferrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol. 2006;149(2):133–135. Itoga T, Matsumoto T, Takeuchi H, et al. Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis. Pathol Int. 2003;53(6):371–375. Morotti M, Valenzano Menada M, Venturini PL, Ferrero S. Bevacizumab in endometrial cancer treatment. Expert Opin Biol Ther. 2012;12(5):649–658. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490–501. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Morotti, M., Ferrero, S. Antiangiogenic Drugs in the Treatment of Endometriosis. Reprod. Sci. 20, NP1–NP2 (2013). https://doi.org/10.1177/1933719112468955 Published: Issue date: DOI: https://doi.org/10.1177/1933719112468955

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Antibodies, Monoclonal, Humanized Disease Models, Animal Endometriosis Niacinamide Phenylurea Compounds Tretinoin Animals Antibodies, Monoclonal, Humanized Endometriosis Female Niacinamide Phenylurea Compounds Tretinoin

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (5)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:12.052662+00:00
License: CC0 · commercial use OK